Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
Clinical trial NCT07256392 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT07256392
- Sponsor
- Celldex Therapeutics
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-11-25
- Primary completion
- 2028-09-01
- Enrollment
- 1370
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.